Uterine Cancer
Also known as: Endometrial cancer, Uterus, Womb, Myometrium, Uterine
Methodology & AI Transparency ⓘ
Uterine Cancer Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is uterine cancer? Uterine cancer is a cancer that forms in tissues of the uterus , which is sometimes called the womb.
- 2 Real-world patient consensus: Clinical coding for Uterine Cancer uses ICD-10 C55 across Cancer & Oncology specialty care.
- 3 Typical cash cost range: Differential triage of Uterine Cancer (C55) utilizes targeted/immunotherapy [Uterine Cancer C55].
- 4 Top reported side effects / signs: Key Cancer & Oncology biomarkers for Uterine Cancer (C55): Complete Blood Count in Uterine Cancer (C55: (ANC, Hemoglobin, Platelets)) & Comprehensive Metabolic & in Uterine Cancer (C55: Organ Function Panel) (Preserved renal/hepatic clearance (C55)).
Ask our AI Specialists anything about Uterine Cancer
What Is Uterine Cancer?
What is uterine cancer? Uterine cancer is a cancer that forms in tissues of the uterus , which is sometimes called the womb. The uterus is the place where a fetus grows during pregnancy. There are two types of uterine cancer: Endometrial cancer is the most common type. This type of cancer begins in the cells lining the uterus, known as the endometrium. Uterine sarcoma is a rare, more aggressive cancer that is harder to treat. This type of cancer begins in muscle or other tissues in the uterus. Who is more likely to develop uterine cancer? Uterine cancer usually happens after menopause. The cause is unknown.
Pathophysiology, Underlying Causes & Clinical Presentation
Uterine Cancer (C55) alters cancer & oncology homeostasis through local tissue remodeling [Uterine Cancer C55]; Cross-referenced with NIH MeSH (Uterine Neoplasms), clinical remission targets Comprehensive Metabolic & in Uterine Cancer (C55: Organ Function Panel) within Preserved renal/hepatic clearance (C55).
Common Symptoms & Clinical Signs
- • Endometrial cancer is the most common type. This type of cancer begins in the cells lining the uterus, known as the endometrium
- • Uterine sarcoma is a rare, more aggressive cancer that is harder to treat. This type of cancer begins in muscle or other tissues in the uterus
- • Presentation of Uterine Cancer (C55): unexplained bleeding, chronic in Uterine Cancer (C55: hoarseness/cough, or progressive)
- • Secondary Uterine Cancer clinical sign: abnormality detected early in Uterine Cancer (C55: on age-appropriate screening)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Uterine Cancer Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C55 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Uterine Cancer (C55: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C55) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Uterine Cancer (C55: Organ Function Panel) | Preserved renal/hepatic clearance (C55) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Uterine Cancer (C55: Genomic Staging) | Guideline-concordant surveillance (C55) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Uterine Cancer
Treatment selection for Uterine Cancer depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Uterine Cancer)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Pain Reduction in Linzagolix-Treated Patients With Uterine Fibroids: A Secondary: What a 1,012-Participant Study Found This analysis showed that reductions in pain were significantly mediated by reductions in HMB (all doses) and FV (200 mg alone) in linzagolix-treated women with UFs. BJOG : an international journal of obstetrics and gynaecology • 2025-08-15 • Phase III Randomized Trial | N = 1,012 | 96/100 | PMID 40326221 ↗ |
| New Insights on Relugolix combination therapy in European women with symptomatic uterine: What a 388-Participant Study Found In European women with UF and HMB, once-daily relugolix-CT vs. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology • 2023-08-17 • Phase III Randomized Trial | N = 388 | 93/100 | PMID 37634528 ↗ |
| New Insights on Implementation of the Study Participant Feedback Questionnaire to understand: What a 371-Participant Study Found Participants reported positive experiences in the INTERLINK-1 study as evaluated by the SPFQ. BMJ open • 2025-10-28 • Phase III Randomized Trial | N = 371 | 93/100 | PMID 41151963 ↗ |
| What the Latest Evidence Really Says About Effects of sildenafil citrate on intrauterine growth Sildenafil citrate increases birth weight and prolonged pregnancies but did not affect stillbirth rate, neonatal death, and NICU admission. BMC pregnancy and childbirth • 2023-06-02 • Meta-Analysis | Multi-cohort | 92/100 | PMID 37268873 ↗ |
| Can This Approach Help? Inside the Latest Research on QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the The OS benefit provided by quizartinib in. Archives of pathology & laboratory medicine • 2025-09-02 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40892059 ↗ |
Uterine Cancer Patient Community & “People Like Me” Threads
Filter Uterine Cancer community threads and patient logs by age, biological sex, dosage, and treatment duration.